As a Zenith shareholder I'm not too happy about putting all those 13 ongoing trial eggs into one, fragile, basket. It's not as sure a shot as the Salesman Don likes to pitch it as. If Zenith lends money for the trial, it should be done on market terms, and that probably means getting more out of the deal than a 6-12% royalty that they already have.

Frankly I think Zenith would do better to fund its own trials and spread the risk out a little.